About the Event
Diabetes is one of the most common chronic illnesses in the United States, affecting over 34.2 million people. Two major complications associated with diabetes are kidney disease and retinal disease in the eyes and both are caused by inflammation of the microvasculature.
InflammX Therapeutics has developed Xiflam, a once daily pill that’s proven effective in regulating out of control inflammation in both the eyes and liver. In a recent test in small animals that were born with diabetes and had significant impairment of visual function at 4 weeks, Xiflam reduced inflammation, resolved the microvascular pathology, and significantly restored visual function.
Join this webinar to hear InflammX CEO, Dr. Brian Levy share details of this very promising development in the treatment of two of the most common and devastating side effects of diabetes.